Creative Touch Permanent Makeup and Aesthetics

Three converging mechanisms drive perimenopausal skin change: reduced systemic oestrogen from declining ovarian synthesis, reduced local oestrogen production within skin tissue itself, and progressive downregulation of oestrogen receptor expression in skin cells. The result is a simultaneous shift across all skin layers – dermal collagen loss accelerates, fibroblast senescence increases, the epidermal renewal cycle slows, barrier lipid synthesis declines constitutively, sebaceous output falls, and the skin microbiome shifts toward a less protective composition. Because oestrogen receptors are expressed across keratinocytes, dermal fibroblasts, sebocytes, and the cells of the follicular unit, the hormonal withdrawal affects all of these simultaneously rather than sequentially. No single treatment addresses the full picture; the clinical response is always multi-layered.

Why Oestrogen Withdrawal Is Different from General Ageing

Chronological skin ageing is driven primarily by intrinsic cellular mechanisms – fibroblast TGF-β decline, telomere shortening, ROS accumulation – compounded by cumulative UV exposure. Perimenopausal skin change operates through a different initiating mechanism: the withdrawal of a hormone that has been actively supporting skin structure, barrier function, and cellular renewal throughout adult life through receptor-mediated signalling across multiple cell types.

ERβ is the dominant oestrogen receptor in human skin and is highly expressed in the epidermis, dermal fibroblasts, sebaceous glands, eccrine sweat glands, and across all compartments of the hair follicle including the bulge region. ^[10] ERα expression in skin is more restricted, found primarily in sebocytes and dermal fibroblasts, where it plays a specific role in collagen regulation – ERα mediates the stimulatory effect of oestradiol on collagen I synthesis, whilst ERβ maintains the decorin and lumican proteoglycans that govern collagen fibril organisation. ^[5] The loss of both receptors’ signalling simultaneously explains why the structural, barrier, and surface changes of perimenopause arrive together rather than in isolation.

The Dermal Layer: Collagen, Elastin, and Ground Substance

The dermal consequences of oestrogen withdrawal are the most structurally significant and the most extensively documented. Collagen content in the first five years after menopause declines by up to 30%, with research confirming that the rate of collagen degradation correlates more strongly with oestrogen deficiency than with chronological age – meaning post-menopausal collagen loss is not simply ageing running faster, but a mechanistically distinct oestrogen-dependent process. ^[9]

The mechanism involves multiple converging pathways. Oestrogen withdrawal reduces TGF-β1 signalling in dermal fibroblasts, impairing the primary growth factor drive for procollagen transcription. Simultaneously, MMP-1 and MMP-3 are upregulated, accelerating collagen and elastin degradation. Fibroblast responsiveness to direct TGF-β stimulation declines with increasing fibroblast senescence, and the pro-senescent M1 macrophage environment that accumulates in aged skin accelerates that senescence further. ^[6] The counterintuitive finding – that post-menopausal fibroblasts upregulate procollagen gene transcription in an apparent compensatory response – does not prevent net collagen loss because the maturation pathway downstream of transcription is simultaneously compromised, with impaired procollagen hydroxylation and accelerated MMP degradation consuming the increased transcript before it contributes to the structural matrix.

Ground substance depletion accompanies the collagen changes: hyaluronic acid levels in the dermis decline with oestrogen withdrawal, reducing both the water-binding capacity that provides skin its plumpness and the mechanical tension environment that fibroblasts require for sustained collagen synthesis. The loss of decorin – whose ERβ-dependent maintenance is compromised – disrupts collagen fibril lateral spacing, producing architectural disorganisation of remaining collagen even before quantitative loss becomes the dominant problem.

Elastic fibre fragmentation follows a parallel trajectory, with declining fibroblast capacity reducing new tropoelastin synthesis whilst MMP-12 elastase activity continues degrading existing fibres – the loss of skin recoil and the development of persistent rather than transient expression lines reflecting this accumulated deficit.

The Epidermal Layer: Thinning, Renewal, and Wound Healing

ERβ is highly expressed across all epidermal keratinocyte layers, and oestrogen directly supports keratinocyte proliferation and the regulation of epidermal renewal rate through this receptor. With oestrogen withdrawal, epidermal thickness measurably declines, rete ridges flatten as both ground substance and dermal support diminish, and the keratinocyte renewal cycle slows. The surface consequence is the dull, slightly tired quality of perimenopausal skin – not a cosmetic impression but a reflection of genuinely reduced epidermal turnover.

Wound healing impairment is one of the more clinically significant but underappreciated consequences. Post-menopausal women show delayed re-epithelialisation and reduced collagen deposition compared to pre-menopausal women at controlled wound sites, with these changes reversing with exogenous oestrogen administration. ^[3] Oestrogen enhances dermal fibroblast migration and TGF-β1 secretion during wound repair; its absence slows both. Re-epithelialisation is specifically guided by ERβ, which accelerates keratinocyte migration across the wound surface. ^[11] The practical implication for aesthetics practice is direct: recovery from any treatment that creates a controlled injury cascade – microneedling, RF microneedling, fractional laser – will be measurably slower in post-menopausal skin, and the synthesis response to that cascade will be reduced.

The Barrier Layer: Constitutive Lipid Decline

The barrier changes of perimenopause differ from externally triggered barrier compromise in a critical respect: they are constitutive. The skin is not responding to a trigger that can be removed – it has lost the hormonal support that maintained barrier lipid synthesis capacity. This distinction defines the treatment approach.

Oestrogen supports ceramide synthesis both through direct transcriptional effects on the elongase enzymes responsible for very-long-chain fatty acid production and through maintaining the sebaceous and epidermal lipid environment. With oestrogen withdrawal, ceramide synthesis capacity declines independently of any external disruption; sebum output falls, reducing the surface lipid film that supplements the SC lipid barrier; and TEWL increases as barrier integrity reduces. Because the ceramide deficit is constitutively maintained by the hormonal context rather than driven by an external trigger, it requires sustained external supplementation rather than the trigger-removal approach that resolves early barrier compromise in younger skin.

Oestrogen also directly supports filaggrin expression in keratinocytes; its decline reduces filaggrin independently of the IL-4/ IL-13 cytokine environment, meaning the NMF production pathway faces suppression from both the hormonal and inflammatory axes simultaneously in perimenopausal skin.

The barrier is additionally compromised by the pH shift that follows reduced acid mantle support: declining sebum and reduced NMF production from the slowing epidermal renewal cycle both contribute to a less acidic SC surface, impairing the activity of the ceramide-processing enzymes ( β-glucocerebrosidase and sphingomyelinase) that are pH-dependent. The result is a compounding deficit: less substrate for ceramide production, and reduced enzymatic capacity to process what substrate is available.

The Sebaceous and Microbiome Transition

Sebaceous glands express both ERα and ERβ, and sebum production is directly influenced by the oestrogen/androgen ratio. As oestrogen declines during perimenopause with relative androgen persistence, the initial pattern in some women is a temporary increase in androgen-driven sebaceous activity – producing the paradoxical combination of adult acne and barrier dryness that many perimenopausal women find confusing. This resolves into progressive sebum decline in the post-menopausal years: sebum levels fall by approximately 40% by the sixth decade and continue declining into the seventh. ^[13]

The microbiome consequences of declining sebum are significant and underappreciated. Sebaceous lipids are a primary nutritional substrate for commensal skin bacteria, and their reduction alters the microbial environment in ways that affect skin defence. Lactobacillus abundance is significantly reduced on post-menopausal skin – oestrogen decline reduces glycogen synthesis in epithelial cells, which is required for Lactobacillus proliferation, and the resulting decline in this genus reduces both the acidification of the skin surface and the antimicrobial and anti-inflammatory metabolite production that Lactobacillus provides. ^[9] The resulting pH shift further compounds the enzymatic barrier deficit described above, creating a connected cascade from sebaceous decline through microbiome shift to ceramide processing impairment.

The sebum decline that accompanies oestrogen withdrawal simultaneously removes the primary nutritional substrate for Cutibacterium acnes, which depends on sebum fatty acids for its metabolic activity. The HELIOS cohort study (Pagac et al., 2025) quantified this with precision: C. acnes relative abundance dropped from 79.9% in pre-menopausal women to 32.1% in post-menopausal women – a 60% reduction. ^[8] Since C. acnes propionic acid fermentation is the dominant acidification mechanism on sebaceous sites, this decline removes a second independent surface acidification pathway at the same time as Lactobacillus populations fall. The combined loss compounds the pH-maintenance vulnerability documented above.

One emerging line of research with particular resonance for this presentation is Lactobacillus-derived exosomes, which have been shown to upregulate filaggrin and loricrin expression in keratinocytes in a dose-dependent manner – directly targeting the structural proteins whose expression the perimenopausal microbiome shift, and the broader IL-4/IL-13 cytokine environment, are simultaneously suppressing. ^[2] The connection between the microbiome decline documented in post-menopausal skin and an exosome-based restoration approach targeting filaggrin specifically is not yet clinically established at scale, but the mechanistic thread from declining Lactobacillus abundance to reduced barrier protein expression to Lactobacillus-derived exosome supplementation is coherent and worth tracking.

The Timeline

Perimenopausal skin changes do not begin at the last menstrual period. They begin during the perimenopause – the hormonal transition that can start up to ten years before menopause – as oestrogen levels become erratic rather than simply declining. The irregular fluctuation of the perimenopausal transition can produce abrupt skin shifts that are more disorienting than the more gradual decline of early post-menopause. The 30% collagen loss figure represents the post-menopausal trajectory; dermal, barrier, and epidermal changes are well established before that marker is reached.

The practical implication is that clients in their mid-to-late forties presenting with skin that has changed in ways they don’t fully understand – products that used to work no longer performing, intermittent breakouts alongside increased sensitivity, a general loss of structural quality – may be experiencing perimenopausal skin biology rather than simply ageing or product failure. Accurate framing of the cause is as clinically important as the treatment response.